Tuesday, June 6, 2017
Hassman Research Institute (HRI) announced that Dr. Larry Ereshefsky joined the company as chief scientific officer, Early Phase Development. Dr. Ereshefsky brings to HRI more than 40 years of drug discovery and development experience including leadership roles at University of Texas Health Science and Parexel. Dr. Ereshefsky will be responsible for leading HRI’s efforts and advancing the company’s Early Phase Development Division focusing on diseases. He will report to Dr. Howard Hassman, CSO of HRI.